SCHEMBL252675

SCHEMBL252675

C=CCN(CC=C)c1cc[c]cc1

nearest known ligand 0.43

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CHKA P35790 1/20 0.43
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL821817 0.98 CHKA (0.42) CHKACYP1A2
SCHEMBL6775781 0.88 ALDH1A1 (0.38) CHKA
SCHEMBL851567 0.83 CHKA (0.50) CHKACYP1A2
SCHEMBL3290812 0.78 PYCR1 (0.35)
SCHEMBL4047348 0.77 ESR1 (0.38) CYP1A2
SCHEMBL7162904 0.76 CHKA (0.46) CHKACYP1A2
SCHEMBL83762 0.76 CHKA (0.46) CHKACYP1A2
SCHEMBL6466250 0.76 CHKA (0.46) CHKACYP1A2
SCHEMBL6692403 0.76 CHKA (0.46) CHKACYP1A2
SCHEMBL11032897 0.76 CHKA (0.46) CHKACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4301725-A1 AMINE SYNERGISTS WITH UV-A ABSORPTION Sun Chemical Corporation (US) 2024-01-10 EP claimed
US-RE49735-E1 Oxazolidinones as modulators of MGLUR5 BRISTOL-MYERS SQUIBB COMPANY (US) 2023-11-28 US claimed
EP-4232040-A1 COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS F. Hoffmann-La Roche AG (CH) 2023-08-30 EP claimed
WO-2023118482-A1 AMINE SYNERGISTS WITH UV-A ABSORPTION SUN CHEMICAL CORPORATION (US) 2023-06-29 WO claimed
US-11369584-B2 Andrographolide derivatives and method of using the same for treatment or prevention of fibrosis ZHENGZHOU UNIVERSITY (CN) 2022-06-28 US claimed
WO-2022084210-A1 COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS F. HOFFMANN-LA ROCHE AG (CH) 2022-04-28 WO claimed
US-11279677-B2 Photochromic hydrazone switches THE TRUSTEES OF DARTMOUTH COLLEGE (US) 2022-03-22 US claimed
US-20210253587-A1 TRIAZOLINEDIONE ADDUCT, METHOD FOR PRODUCING TRIAZOLINEDIONE ADDUCT, METHOD FOR PRODUCING ENE COMPOUND, AND METHOD FOR ANALYZING ENE COMPOUND TOKUYAMA CORPORATION (JP) 2021-08-19 US claimed
US-20210122721-A1 BIS-PROPENAMIDE COMPOUNDS AND METHODS OF TREATING CANCER KING ABDULAZIZ UNIVERSITY (SA) 2021-04-29 US claimed
EP-3758706-A2 WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME The Regents Of The University Of Colorado (US) 2021-01-06 EP claimed
EP-0010652-A1 4-Chlorooxazoles, method for their preparation and their use in photoconductive coatings in electrophotography and as optical brighteners HOECHST AKTIENGESELLSCHAFT (DE) 1980-05-14 EP claimed
US-4192677-A ELECTROGRAPHIC CHARGE TRANSFER COMPOUNDS RICOH CO., LTD. (JP) 1980-03-11 US claimed
US-4160671-A ESTER OR AMIDE OF AN O-NAPHTHOQUINONE DIAZIDE SULFONIC ACID, ORGANIC DYE, HALOGEN-CONTAINING DERIVATIVE OF PYRONE OR TRIAZINE HOECHST AKTIENGESELLSCHAFT (DE) 1979-07-10 US claimed
US-4145215-A PHOTOCONDUCTIVE PIGMENTS EASTMAN KODAK COMPANY (US) 1979-03-20 US claimed
US-RE29748-E TRIHALOMETHYL COMPOUND AND BIS(DIALKYLAMINOPHENYL)ALKENE HORIZONS INCORPORATED A DIVISION OF HORIZONS RESEARCH INCORPORATED (US) 1978-08-29 US claimed
US-4061637-A CNS, CARDIOVASCULAR, ANTIINFLAMMATORY, ADRENOLYTIC, ANTIULCER ISTITUTO LUSO FARMACO D'ITALIA S.R.L. (IT) 1977-12-06 US claimed
US-3967965-A HETEROCYCLIC UREAS FUJI PHOTO FILM CO., LTD. (JA) 1976-07-06 US claimed
US-RE28789-E ETHYLENICALLY UNSATURATED MONOMER; RADIATION ABSORBER E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-04-27 US claimed
US-3951654-A CHARGE TRANSPORT SENSITIZER XEROX CORPORATION (US) 1976-04-20 US claimed
US-3944417-A Process for the electrophotographic production of printing plates HOECHST AKTIENGESELLSCHAFT (DT) 1976-03-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122721-A1 BIS-PROPENAMIDE COMPOUNDS AND METHODS OF TREATING CANCER APC, CCNE1, CCNI CHKA 320/4885CYP1A2 141/4885
US-20210253587-A1 TRIAZOLINEDIONE ADDUCT, METHOD FOR PRODUCING TRIAZOLINEDIONE ADDUCT, METHOD FOR PRODUCING ENE COMPOUND, AND METHOD FOR ANALYZING ENE COMPOUND NR2E1, AR, NR5A2 CHKA 2676/4885CYP1A2 100/4885
US-11279677-B2 Photochromic hydrazone switches CRYZ, PIN1, PPOX CHKA 2822/4885CYP1A2 2177/4885
US-11369584-B2 Andrographolide derivatives and method of using the same for treatment or prevention of fibrosis MMP1, CYP27A1, PYGL CHKA 3281/4885CYP1A2 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.